Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
18:16:34 EDT Tue 15 Jul 2025
Enter Symbol
or Name
USA
CA



Z:RDY - DR REDDYS LABORATORIES ADS EACH REPR 1 ORD INR5 - https://www.drreddys.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
RDY - Z1.514.60·14.871.814.54-0.035-0.21,430.720,1625,98414.67  14.70  14.5416.892  12.283516:43:13Jun 0515 min RT 2¢

Recent Trades - Last 10 of 5984
Time ETExPriceChangeVolume
16:43:13Z14.620.06100
16:43:10Z14.620.06100
16:43:09Z14.620.06100
16:43:04Z14.620.06100
16:43:01Z14.620.06100
16:37:30Z14.56 500
16:36:46Z14.600.041,000
16:36:30Z14.600.04500
16:04:12Z14.53-0.031
16:04:08Z14.53-0.031

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-06-05 07:00U:RDYNews ReleaseAlvotech and Dr. Reddy's Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda(TM) (pembrolizumab)
2025-05-09 14:53U:RDYNews ReleaseDr. Reddy's Q4 & Full Year FY25 Financial Results
2025-03-27 11:47U:RDYNews ReleaseBio-Thera and Dr. Reddy's Execute Exclusive Commercialization Agreement for BAT2206, a Proposed Stelara(TM) Biosimilar, and BAT2506, a Proposed Simponi(TM) Biosimilar, for Southeast Asia
2025-03-18 08:35U:RDYNews ReleaseAlvotech and Dr. Reddy's Announce FDA Acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia(TM) and Xgeva(TM)
2025-03-13 10:40U:RDYNews ReleaseDr. Reddy's Issues a Nationwide Recall of Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 mL, in the U.S., due to Mislabeling of Infusion Bag
2025-02-06 07:51U:RDYNews ReleaseDr. Reddy's enters into collaboration with Henlius for commercialization of HLX15 (daratumumab), a biosimilar candidate to Darzalex(TM) & Darzalex Faspro(TM) in the U.S., and Europe
2025-01-23 12:35U:RDYNews ReleaseDr. Reddy's Q3 & 9MFY25 Financial Results
2024-11-28 06:15U:RDYNews ReleaseDr. Reddy's launches Toripalimab in India, the first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma
2024-11-26 08:07U:RDYNews ReleaseDr. Reddy's Laboratories and Senores Pharmaceuticals, Inc. Announce the Launch of Ivermectin Tablets USP, 3 mg in US Market
2024-11-05 09:59U:RDYNews ReleaseDr. Reddy's Q2 & H1FY25 Financial Results
2024-10-25 07:40U:RDYNews ReleaseDr. Reddy's Named by Science Magazine in Top 20 Global Pharma Employers List for Third Consecutive Year
2024-10-14 09:47U:RDYNews ReleaseDr. Reddy's Launches Comprehensive Menopause Support Program and Training for Employees During Menopause Awareness Month
2024-10-08 11:32U:RDYNews ReleaseAurigene Oncology Limited Announces Promising Results of Phase 1 Study for India's First Trial for Novel Autologous CAR-T Cell Therapy for Multiple Myeloma
2024-10-02 11:10U:RDYNews ReleaseDr. Reddy's signs voluntary licensing agreement with Gilead Sciences to manufacture and commercialise Lenacapavir in India and other countries
2024-08-20 14:42U:RDYNews ReleaseDr. Reddy's Laboratories, Aurigene Pharmaceutical Services, and Kainomyx Announce Potential Partnership for Joint Development of Affordable Anti-Malarial Drug
2024-07-29 11:55U:RDYNews ReleaseDr. Reddy's Receives Positive CHMP Opinion From European Medicines Agency for Its Proposed Rituximab Biosimilar
2024-07-27 09:51U:RDYNews ReleaseDr. Reddy's Q1FY25 Financial Results